Similarly, an inhibitor of LRRK2 kinase activity is being tested in PD carriers of the LRRK2 G2019S mutation, which appears to abnormally elevate LRRK2’s kinase’ activity (NIH National Library of Medicine, 2022a,b). The gene discussed is LRRK2; the disease is Parkinson disease.